Crohns Disease Emergency Guide, Anyone who has Crohn’s disease will know that a flare-up can often come out of the blue. It can occur anywhere along the GI tract from the mouth to the anus and causes additional symptoms like joint pain and chronic fatigue. Trying to limit the severity and length of a flare-up is imperative, as well as trying to find a way to prevent them from happening in the first place.
Causes of Flare-Ups
According to healthline.com, some of the causes of Crohn’s disease reactivation could be smoking, stress, other illnesses, nonsteroid anti-inflammatory drugs, changes in Crohn’s medication, and antibiotics. Some patients find that certain foods trigger their Crohn’s disease, particularly gluten and dairy.
Read More: Crohn’s Disease Flare-Ups: An Emergency Guide
Crohns Disease Affects Brain Function, A new research has found that Crohn’s disease not only affects the gut but also has an impact on the brain. Crohn’s disease is a chronic inflammatory bowel disease characterized by inflammation of the digestive, or gastrointestinal, tract.
The research published in the UEG Journal on Wednesday shows that those with Crohns disease experience slower response times compared with individuals who do not have the disease. The cognitive response times were 10 percent slower than normal and significantly corresponded with symptoms of active inflammation, including abdominal pain and fatigue, the study finds. The results show the presence of a mild cognitive impairment in Crohn’s patients. This also supports frequent complaints from patients related to lack of concentration, clouding of thought and memory lapses. The study also found that Crohn’s patients had a higher median depression score and a poorer rate of sleep quality.
“These results reinforce the notion that Crohn’s has a wide range of multi-systemic consequences with the impact of the disease affecting patients not only within but well beyond the digestive tract,” Dr. Daniel van Langenberg, the lead researcher of the study, said in a statement. “The findings appear consistent with experiments that have shown that bowel inflammation results in an upregulation of inflammatory hippocampus activity in the brain. This, in turn, might account for the slower response times that were observed in the study.”
Crohn’s disease, which is one of the two main forms of inflammatory bowel disease, can cause abdominal pain, diarrhea, weight loss, anemia, and fatigue. There is no cure for Crohn’s disease but medications such as steroids and immunosuppressants can be used to slow the progression of the disease.
Commenting on the research, Gigi Veereman, UEG inflammatory bowel disease expert, said: “This research highlights the need for regular interventions with multi-disciplinary IBD teams to address the wide issues that are presented with Crohn’s disease. This will enable a greater understanding of this complex condition and therefore improve the service and care offered to each patient.”
RedHill Biopharma announced the publication of a peer-review article demonstrating the potential efficacy of RHB-104 for the treatment of Mycobacterium avium subspecies paratuberculosis (MAP) infection-associated Crohn’s disease.
The article was authored by researchers from the Burnett School of Biomedical Sciences at the University of Central Florida (UCF) College of Medicine and titled “RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn’s disease associated with Mycobacterium paratuberculosis.” The study was published in the journal Gut Pathogens.
RHB-104 is a patented oral antibiotic combination therapy with strong properties at the intracellular, anti-mycobacterial and anti-inflammatory levels. RHB-104 was grounded on emerging evidence that supports the hypothesis that Crohn’s disease is caused by MAP infections in susceptible patients.
The article describes a preclinical study designed to evaluate the efficacy of RHB-104 active components (antibiotics clarithromycin, clofazimine and rifabutin) against MAP strains isolated from Crohn’s patients’ blood, tissue and milk.
The preclinical study’s results showed that the active components of RHB-104, individually or dually combined, were not as effective against all microorganisms as triple combinations at minimum inhibitory concentration levels.
Based on the results, the research team concluded that lower concentrations of the triple active components combination in RHB-104 could provide a better synergy against MAP growth activity. Consequently, the authors recommend the administration of RHB-104 for long-term treatment of Crohn’s disease.
“We are pleased with the important findings described in this article which provide further validation of the synergistic activity and potential efficacy of RHB-104 in eradicating Mycobacterium avium subspecies paratuberculosis, or MAP, – a suspected etiological agent of Crohn’s disease and possibly additional autoimmune, inflammatory and mycobacterial diseases,” Reza Fathi, RedHill’s senior vice president of Research & Development, in a press release. “The results from this study suggest that RHB-104, if approved, could become a new and effective therapy for the treatment of Crohn’s disease.”
RHB-104 is currently in a first randomized, double-blind, placebo-controlled Phase 3 clinical trial titled “Efficacy and Safety of Anti-MAP Therapy in Adult Crohn’s Disease (MAP US)” evaluating the drug candidate’s performance in the treatment of Crohn’s disease. The study is taking place in the United States, Canada, Israel and Australia, among some additional countries. Interim data is expected in the second half of 2016, after 50% of the 270 patients enrolled in the study will have completed 26 weeks of treatment.